126554-50-5 Usage
Description
(6aR,9R,10aR)-7-allyl-N9-[3-(dimethylamino)propyl]-N4-ethyl-N9-(ethylcarbamoyl)-6a,7,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-4,9(6H)-dicarboxamide is a complex organic compound with a unique molecular structure. It is characterized by its hexahydroindoloquinoline core, which is further modified with various functional groups, including allyl, dimethylamino, and ethylcarbamoyl moieties. (6aR,9R,10aR)-7-allyl-N9-[3-(dimethylamino)propyl]-N4-ethyl-N9-(ethylcarbamoyl)-6a,7,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-4,9(6H)-dicarboxamide is likely to have specific interactions with biological targets due to its intricate structure and functional groups.
Uses
Used in Pharmaceutical Industry:
(6aR,9R,10aR)-7-allyl-N9-[3-(dimethylamino)propyl]-N4-ethyl-N9-(ethylcarbamoyl)-6a,7,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-4,9(6H)-dicarboxamide is used as a pharmaceutical compound for its potential interaction with dopamine D2-receptors. As an impurity of Cabergoline, a known dopamine D2-receptor agonist, this compound may have implications in the treatment of various conditions related to dopamine receptor dysregulation, such as Parkinson's disease.
Used in Research and Development:
In the field of research and development, this compound can be utilized as a starting material or a tool to study the structure-activity relationships of dopamine D2-receptor agonists. Understanding the effects of its unique structural features on receptor binding and activation can provide valuable insights into the design of more effective and selective therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 126554-50-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,6,5,5 and 4 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 126554-50:
(8*1)+(7*2)+(6*6)+(5*5)+(4*5)+(3*4)+(2*5)+(1*0)=125
125 % 10 = 5
So 126554-50-5 is a valid CAS Registry Number.
126554-50-5Relevant articles and documents
Synthesis of European pharmacopoeial impurities A, B, C, and D of cabergoline
Wagger, Jernej,Pozes, Aljaz,Pozgan, Franc
, p. 23146 - 23156 (2013)
For the use of analytics, European pharmacopoeial impurities A, B, C, and D of cabergoline were synthesized. Ergocryptine was chosen as a starting material and synthesis was accomplished via two approaches, different in length and stereochemical outcome. A longer, indirect approach was realized through otherwise problematic oxidations of the 9,10-dihidrolysergol derivative, to the corresponding aldehyde and carboxylic acid. This was achieved by the use of activated DMSO and a Pinnick oxidation sequence. All four synthesized impurities are used as analytical standards in cabergoline manufacturing processes.
